Chimeric Antigen Receptor T-Cell Therapy: A New Emerging Landscape in Autoimmune Rheumatic Diseases

Chimeric antigen receptor T-cell (CAR-T) therapy, an innovative immune cell therapy, has revolutionised the treatment landscape of haematological malignancies. The past two years have witnessed the successful application of CD19-targeting CAR constructs in refractory cases of autoimmune rheumatic diseases, including systemic lupus erythematosus, systemic sclerosis, and anti-synthetase syndrome. In comparison to existing B-cell depletion therapies, targeting CD19 has demonstrated a more rapid and profound therapeutic effect, enabling drug-free remission with manageable adverse events. These promising results necessitate validation through long-term, large-sample, randomized controlled studies. Corroborating the role of CAR-T therapy in refractory rheumatological disorders and affirming safety, efficacy and durability of responses are the aims of future clinical studies. Optimising the engineering strategies and better patient selection are also critical to further refining the successful clinical implementation of CAR-T therapy.